XNAS
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
Struggling biotech secures $570K convertible debt from Streeterville Capital amid **$0.18 EPS miss** and 55% revenue shortfall, highlighting urgent liquidity needs.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | Q1 2026 | -0.10 | -0.28 | -180.00% | $353,375 | ❌ Miss | -2.33% | -24.81% | — |
| 2026-03-31 | FY 2025 | — | -0.76 | — | $2.0M | — | -4.26% | +1.60% | -15.43% |
Showing last 2 quarters.